A first-in-human KRAS-targeted pancreatic cancer prevention vaccine was found to be safe, elicited durable immune responses in 90% of high-risk participants, and showed encouraging signs of slowing or reversing precancerous lesions. The post KRAS-Targeted Vaccine Crosses First Clinical Milestone in Pancreatic Cancer Prevention appeared first on GEN – Genetic Engineering and Biotechnology News.
You may also like
Genetic Study Links Excessive Sweating to Neurological...
Modular Antibody–ADC Click Chemistry Overcomes Tumor...
See, Blind Mice: Consortium’s Drugs Restore Sight
Jasper gets a lifeline in merger with immune drugmaker...
Arbutus, Sanofi escalate mRNA patent fights;...
GSK shelves cough drug acquired in $2B deal
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.